- Cannabix Technologies (CSE:BLO), a leading developer of marijuana and alcohol breath testing devices, has announced significant updates to its Cannabix marijuana breathalyzer (CMB) technology
- The breath collection unit now features a smaller, lightweight, and more ergonomic design, making it easier to handle and use
- These developments come at a crucial time as the need for marijuana breath detection intensifies in the United States and globally
- Cannabix stock (CSE:BLO) opened trading at $0.31
Cannabix Technologies (CSE:BLO), a leading developer of marijuana and alcohol breath testing devices, has announced significant updates to its Cannabix marijuana breathalyzer (CMB) technology. These enhancements are designed to meet emerging regulatory requirements as the company prepares for market introduction.
Key updates to the breath collection unit (BCU):
- Ergonomic design: The BCU now features a smaller, lightweight, and more ergonomic design, making it easier to handle and use.
- Rechargeable battery: A new removable, long-lasting, rechargeable Li-ion battery has been incorporated, allowing for easy battery replacement.
- Sample collection: The sample collection cartridge has been modified to collect either a single sample or dual samples, consistent with federally regulated programs that require simultaneous A & B sample collection. Additionally, a new ambient air collection through a second cartridge is now available.
- Quality assurance: New features include an “on demand” periodic quality assurance check, a startup self-check feature, and a streamlined user interface.
These developments come at a crucial time as the need for marijuana breath detection intensifies in the United States and globally. A recent New York Times article, “As Marijuana Use Grows, Effect on Road Safety Remains a Blind Spot”, highlights the lack of tools to detect cannabis-impaired driving and the limitations of existing testing methods for delta-9 THC. The article references a 2019 survey by the AAA Foundation for Traffic Safety, which found that an estimated 14.8 million drivers in the U.S. reported driving within one hour after using marijuana, with 70 per cent of Americans believing it’s unlikely a driver will get caught by police for driving while high.
“Cannabix is at the forefront of marijuana breathalyzer technology, and we anticipate that 2025 will hold significant milestones as the company has matured its technology, partnerships and business opportunities,” Cannabix CEO, Rav Mlait, stated in a news release. “In the U.S., cannabis legalization has grown to 39 states for medical use and 24 states legalized for recreational use. This represents a major growth opportunity for Cannabix in the drug testing segment.”
Cannabix’s marijuana breathalyzer technology focuses on detecting “recent use” of delta-9 THC, unlike widely used urine, blood, and saliva methods that can detect delta-9 THC many hours, days, or even weeks after consumption. This focus on recent use is critical for addressing the immediate effects of cannabis on driving and road safety.
Cannabix is rapidly advancing its marijuana breathalyzer technology, with key validation work well underway in the United States. The company’s efforts are poised to make a significant impact on road safety and the detection of cannabis-impaired driving.
Cannabix Technologies develops marijuana and alcohol breathalyzer technologies for law enforcement, workplaces and laboratories. Cannabix is working to develop delta-9 THC and alcohol screening devices.
Cannabix stock (CSE:BLO) opened trading at $0.31.
Join the discussion: Find out what everybody’s saying about this stock on the Cannabix Technologies Bullboard, and check out the rest of Stockhouse’s stock forums and message boards.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.
(Top image via Cannabix Technologies Inc.)